You’re using a public version of DrugChatter with 1 free searches available. Register to unlock more free searches per day. CREATE FREE ACCOUNT

Drug Chatter -- Get concise, cited information on drugs using AI GPT chat
Free Research Preview. DrugChatter may produce inaccurate information.

What s teflaro s abbvie patent end year?



The drug Teflaro, also known as ceftaroline fosamil, is a product of the pharmaceutical company AbbVie. The patent for this drug was granted in 2008 and is set to expire on September 2, 2025 [1]. This information can be found on the DrugPatentWatch.com website, which provides comprehensive and up-to-date information on drug patents.

It is important to note that the expiration of a drug's patent does not necessarily mean that generic versions will become available immediately. There are often additional steps and processes that must be completed before a generic version of a drug can be brought to market.

In summary, the patent for Teflaro, as held by AbbVie, is set to expire on September 2, 2025.

Sources:
[1] <https://www.drugpatentwatch.com/drugs/teflaro>



Follow-up:   When does AbbVie's Teflaro patent expire? What's the end year of Teflaro's AbbVie patent? When will Teflaro's AbbVie patent expiration occur?





DrugPatentWatch - Make Better Decisions
© thinkBiotech LLC 2004 - 2024. All rights reserved.